Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C27H34FN5O2 |
Molecular Weight | 479.5896 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1[C@@H]2CC[C@H]3[C@@H]4CC[C@H](C(=O)NCC5=NC6=NC=CC=C6N5)[C@@]4(C)CC[C@@H]3[C@@]2(C)C=C(F)C1=O
InChI
InChIKey=GBEUKTWTUSPHEE-JWJWXJQQSA-N
InChI=1S/C27H34FN5O2/c1-26-11-10-17-15(6-9-21-27(17,2)13-19(28)25(35)33(21)3)16(26)7-8-18(26)24(34)30-14-22-31-20-5-4-12-29-23(20)32-22/h4-5,12-13,15-18,21H,6-11,14H2,1-3H3,(H,30,34)(H,29,31,32)/t15-,16-,17-,18+,21+,26-,27+/m0/s1
MK-0773 is an orally active selective androgen receptor modulator. The safety and efficacy of MK-0773 was evaluated in sarcopenic elderly women. The MK-0773- induced improvements in lean body mass were not accompanied by statistically significant improvements in physical function. Higher dose of MK-0773 or longer duration of therapy might have resulted in improvements in physical function, but liver transaminase elevations likely preclude further development of MK-0773. Drug-candidate had been in phase I clinical trials for the treatment of osteoporosis.
Originator
Approval Year
Sample Use Guides
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL3545333
Created by
admin on Tue Oct 22 15:40:50 UTC 2019 , Edited by admin on Tue Oct 22 15:40:50 UTC 2019
|
PRIMARY | |||
|
11950726
Created by
admin on Tue Oct 22 15:40:50 UTC 2019 , Edited by admin on Tue Oct 22 15:40:50 UTC 2019
|
PRIMARY | |||
|
606101-58-0
Created by
admin on Tue Oct 22 15:40:50 UTC 2019 , Edited by admin on Tue Oct 22 15:40:50 UTC 2019
|
PRIMARY | |||
|
MK-0773
Created by
admin on Tue Oct 22 15:40:50 UTC 2019 , Edited by admin on Tue Oct 22 15:40:50 UTC 2019
|
PRIMARY |
ACTIVE MOIETY